Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®

Antiviral Research

Volumn 97, Issue 3, 2013, Pages 301-311

  Santos Fernandes, Élida ^a   Beltrame, Cristiana O ^a   Byrd, Chelsea M ^b   Cardwell, Kara B ^b   Schnellrath, Laila C ^a   Medaglia, Maria Luiza G ^a   Hruby, Dennis E ^b   Jordan, Robert ^b,c   Damaso, Clarissa R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b SIGA Technologies Incorporated   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Antiviral agent; Cantagalo virus; Poxvirus; ST 246; Vaccinia virus

Indexed keywords

BETA GALACTOSIDASE; TECOVIRIMAT;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CANTAGALO VIRUS; COMET ASSAY; DAIRY CATTLE; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CATTLE; CATTLE DISEASES; FEMALE; ISOINDOLES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; SEQUENCE ALIGNMENT; VIRAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; CANTAGALO VIRUS; COWPOX VIRUS; MUS; ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 84873027883     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.11.010     Document Type: Article

References (42)

1. Alcami A., Smith G.L. A mechanism for the inhibition of fever by a virus. Proc. Natl. Acad. Sci. USA 1996, 93:11029-11034.
2. Blasco R., Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 1991, 65:5910-5920.
3. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181:10-19.
4. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 1985, 5:3403-3409.
5. Chen Y., Honeychurch K.M., Yang G., Byrd C.M., Harver C., Hruby D.E., Jordan R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009, 6:44.
6. Damaso C.R., Esposito J.J., Condit R.C., Moussatche N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277:439-449.
7. Damaso C.R., Moussatche N. Protein synthesis in vaccinia virus-infected cells. I. Effect of hypertonic shock recovery. Arch. Virol. 1992, 123:295-308.
8. Damaso C.R., Reis S.A., Jesus D.M., Lima P.S., Moussatche N. A PCR-based assay for detection of emerging vaccinia-like viruses isolated in Brazil. Diagn. Microbiol. Infect. Dis. 2007, 57:39-46.
9. de Souza Trindade G., da Fonseca F.G., Marques J.T., Nogueira M.L., Mendes L.C., Borges A.S., Peiro J.R., Pituco E.M., Bonjardim C.A., Ferreira P.C., Kroon E.G. Aracatuba virus: a vaccinialike virus associated with infection in humans and cattle. Emerg. Infect. Dis. 2003, 9:155-160.
10. Donatele D.M., Travassos C.E.P.F., Leite J.A., Kroon E.G. Epidemiologia da poxvirose bovina no Estado do Espírito Santo, Brasil. Braz. J. Vet. Res. Anim. Sci. 2007, 44:275-282.
11. Duraffour S., Andrei G., Snoeck R. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs 2010, 13:181-191.
12. Duraffour S., Snoeck R., de Vos R., van Den Oord J.J., Crance J.M., Garin D., Hruby D.E., Jordan R., De Clercq E., Andrei G. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 2007, 12:1205-1216.
13. Duraffour S., Vigne S., Vermeire K., Garcel A., Vanstreels E., Daelemans D., Yang G., Jordan R., Hruby D.E., Crance J.M., Garin D., Andrei G., Snoeck R. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir. Ther. 2008, 13:977-990.
14. Foo C.H., Lou H., Whitbeck J.C., Ponce-de-Leon M., Atanasiu D., Eisenberg R.J., Cohen G.H. Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology 2009, 385:368-382.
15. Golden J.W., Hooper J.W. The strategic use of novel smallpox vaccines in the post-eradication world. Expert Rev. Vaccines 2011, 10:1021-1035.
16. Grosenbach D.W., Jordan R., King D.S., Berhanu A., Warren T.K., Kirkwood-Watts D.L., Tyavanagimatt S., Tan Y., Wilson R.L., Jones K.F., Hruby D.E. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008, 26:933-946.
17. Jesus D.M., Costa L.T., Goncalves D.L., Achete C.A., Attias M., Moussatche N., Damaso C.R. Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J. Virol. 2009, 83:11477-11490.
18. Jesus D.M., Moussatche N., Damaso C.R. In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC. Int. J. Antimicrob. Agents 2009, 33:75-79.
19. Jordan R., Chinsangaram J., Bolken T.C., Tyavanagimatt S.R., Tien D., Jones K.F., Frimm A., Corrado M.L., Pickens M., Landis P., Clarke J., Marbury T.C., Hruby D.E. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 2010, 54:2560-2566.
20. Jordan R., Tien D., Bolken T.C., Jones K.F., Tyavanagimatt S.R., Strasser J., Frimm A., Corrado M.L., Strome P.G., Hruby D.E. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 2008, 52:1721-1727.
21. Jordao A.K., Afonso P.P., Ferreira V.F., de Souza M.C., Almeida M.C., Beltrame C.O., Paiva D.P., Wardell S.M., Wardell J.L., Tiekink E.R., Damaso C.R., Cunha A.C. Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture. Eur. J. Med. Chem. 2009, 44:3777-3783.
22. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46:991-995.
23. Medaglia M.L., Pessoa L.C., Sales E.R., Freitas T.R., Damaso C.R. Spread of cantagalo virus to northern Brazil. Emerg. Infect. Dis. 2009, 15:1142-1143.
24. Megid J., Appolinario C.M., Langoni H., Pituco E.M., Okuda L.H. Vaccinia virus in humans and cattle in southwest region of Sao Paulo state, Brazil. Am. J. Trop. Med. Hyg. 2008, 79:647-651.
25. Melamed S., Paran N., Katz L., Ben-Nathan D., Israely T., Schneider P., Levin R., Lustig S. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine 2007, 25:7743-7753.
26. Moussatche N., Damaso C.R., McFadden G. When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J. Infect. Dev. Ctries 2008, 2:156-173.
27. Nagasse-Sugahara T.K., Kisielius J.J., Ueda-Ito M., Curti S.P., Figueiredo C.A., Cruz A.S., Silva M.M., Ramos C.H., Silva M.C., Sakurai T., Salles-Gomes L.F. Human vaccinia-like virus outbreaks in Sao Paulo and Goias States, Brazil: virus detection, isolation and identification. Rev. Inst. Med. Trop. Sao Paulo 2004, 46:315-322.
28. Painter W., Robertson A., Trost L.C., Godkin S., Lampert B., Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 2012, 56:2726-2734.
29. PBR, 2012. Poxvirus Bioinformatics Resource Center. Available at:. http://www.poxvirus.org.
30. Quenelle D.C., Buller R.M., Parker S., Keith K.A., Hruby D.E., Jordan R., Kern E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 2007, 51:689-695.
31. Quenelle D.C., Collins D.J., Kern E.R. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 2004, 63:33-40.
32. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48:404-412.
33. Quixabeira-Santos J.C., Medaglia M.L., Pescador C.A., Damaso C.R. Animal movement and establishment of vaccinia virus cantagalo strain in Amazon biome, Brazil. Emerg. Infect. Dis. 2011, 17:726-729.
34. Reis S.A., Moussatche N., Damaso C.R. FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture. J. Appl. Microbiol. 2006, 100:1373-1380.
35. Reynolds M.G., Damon I.K. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 2012, 20:80-87.
36. Roper R.L., Moss B. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J. Virol. 1999, 73:1108-1117.
37. Sanes J.R., Rubenstein J.L., Nicolas J.F. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J. 1986, 5:3133-3142.
38. Schnellrath L.C., Damaso C.R. Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture. Int. J. Antimicrob. Agents 2011, 38:435-441.
39. Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 2009, 53:1007-1012.
40. Smith S.K., Self J., Weiss S., Carroll D., Braden Z., Regnery R.L., Davidson W., Jordan R., Hruby D.E., Damon I.K. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J. Virol. 2011, 85:9176-9187.
41. Vorou R.M., Papavassiliou V.G., Pierroutsakos I.N. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 2008, 21:153-156.
42. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005, 79:13139-13149.